Search Results for “surgical” – Page 20 – media

With Phase 3 Studies Ongoing in Bladder Cancer, CG Oncology Plots Course for IPO

CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follow the report of interim efficacy data showing a 75% complete response rate. By FRANK VINLUAN When bladder cancer does not respond to the current standard of care therapy, the next treatment option is surgery to completely remove the bladder. CG Oncology aims to give patients another choice. The biotech has reached late-stage development with an oncolytic virus and it’s now looking to the public markets to finance clinical testing. Irvine, California-based CG has not yet set financial terms for the planned offering, outlined in paperwork filed with the Securities and Exchange Commission this past week. IPO research firm Renaissance Capital estimates the stock offering could raise up to $100 million. CG has applied for a Nasdaq listing under the stock symbol “CGON.” CG is developing treatments for ...
- Source: drugdu
- 82
- January 9, 2024
First to take 12 months of market exclusivity! Zhengda Tianqing Everolimus Tablets first generic listing

On December 26, Zhengda Tianqing received the Certificate of Drug Registration approved by the State Drug Administration, approving the registration and listing of Everolimus Tablets (trade name: Chingvishi). Evervimox Tablet is not only the first generic in China, but also the first product that has been granted 12 months of market exclusivity due to “first generic approval + first successful patent challenge” since the implementation of the mechanism for early resolution of drug patent disputes (Drug Patent Linkage System) in China. The approved indications of Zhengda Tianqing Everolimus Tablets are: (1) Adult patients with advanced renal cell carcinoma who have failed prior treatment with sunitinib or sorafenib. (2) Adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately differentiated or highly differentiated) progressive pancreatic neuroendocrine tumors. (3) Adult patients with unresectable, locally advanced or metastatic, well-differentiated, progressive non-functional gastrointestinal or lung-derived neuroendocrine tumors (NET). (4) Adult and pediatric patients with ...
- Source: drugdu
- 187
- January 7, 2024
HANSIZHUANG Combined with Chemotherapy for the First-line Treatment of sqNSCLC

Shanghai, China, January 5th, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that ASTRUM-004, Henlius’ pivotal phase 3 clinical study of anti-PD-1 mAb HANSIZHUANG (serplulimab) plus chemotherapy as first-line treatment for previously untreated locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC), was published in Cancer Cell, a highly regarded oncology journal with an impact factor of 50.3. This publication serves as further evidence of the exceptional performance of HANSIZHUANG in the field of lung cancer. The study was led by Professor Caicun Zhou from Shanghai Pulmonary Hospital. Results of the overall population ASTRUM-004 were initially presented at the IASLC 2023 World Conference on Lung Cancer (WCLC 2023) in the form of oral presentation. Additionally, the data from its Asian subgroup were showcased in a poster session at the European Society of Medical Oncology Asia (ESMO Asia) Congress 2023. Previously in 2022, the new drug application (NDA) of serplulimab for ...
- Source: drugdu
- 85
- January 7, 2024
Johns Hopkins researchers find minimal regret after gender affirming surgery

In a Viewpoint article published Dec. 27, 2023, in JAMA Surgery, three Johns Hopkins researchers urge the medical community to dismiss a widely held, but scientifically unsupported belief that many people who are transgender and gender diverse (TGD), and undergo gender affirming surgery (GAS), later regret their decision to undergo such procedures. The researchers are: Harry Barbee, Ph.D., assistant professor and interdisciplinary social scientist at the Johns Hopkins Bloomberg School of Public Health; Bashar Hassan, M.D., a postdoctoral research fellow in plastic and reconstructive surgery at the Johns Hopkins Center for Transgender and Gender Expansive Health (CTH) and the University of Maryland Medical Center’s R Adams Cowley Shock Trauma Center; Fan Liang, M.D., medical director at the CTH and assistant professor of plastic and reconstructive surgery at the Johns Hopkins University School of Medicine In their article, the three report findings from a retrospective look at the limited amount of ...
- Source: drugdu
- 125
- December 30, 2023
CMEF 2024

CMEF(full name: China International Medical Equipment Expo) was founded in 1979, held twice a year in the spring and autumn, after more than 40 years of innovation and development, has become the world's leading covering the whole industry chain, scientific and technological innovation, new product launch, business docking, brand communication, academic exchange, trend insight, education and training in one of the medical health technology platform. With the theme of "Innovation and Technology leading the Future", this year's CMEF covers tens of thousands of whole-department and whole-industry chain product technologies and solutions for medical imaging, in vitro diagnosis, medical electronics, medical optics, hospital construction, operating room, disinfection sensor control, medical consumables, orthopedic medical robots, etc.
- Source: drugdu
- 207
- December 27, 2023
Orthofix has positive spine stimulation tech data

BY SEAN WHOOLEY rthofix Medical (Nasadaq: OFIX)+ today announced new data investigating pulsed electromagnetic field (PEMF) stimulation with lumbar spinal fusion. Lewisville, Texas-based Orthofix evaluated PEMF stimulation as an adjunct to lumbar spinal fusion procedures in patients at risk for pseudoarthrosis. Patients treated with the SpinalStim bone growth device demonstrated a high rate of successful fusion. They also showed significant improvements in pain, function and quality of life, despite having risk factors for pseudoarthrosis. SpinalStim, an FDA-approved bone growth stimulation therapy, offers an adjunct treatment for lumbar spinal fusion. It also functions as a nonsurgical treatment for spinal pseudoarthrosis. The device utilizes PEMF technology that provides 360 degrees of treatment coverage around the fusion site. Orthofix says its system has an overall success rate of 92% in treating spinal fusion surgery patients. Researchers published their data evaluating the SpinalStim system in the International Journal of Spine Surgery. Lead author Dr. ...
- Source: drugdu
- 182
- December 27, 2023
da Vinci Innovation & Training Center Celebrates its Second Anniversary

The da Vinci Innovation & Training Center marks its second anniversary. Over the past two years, the center has provided more than 1,300 training sessions for healthcare professionals and conducted training operations related to da Vinci technology and surgeries for over 3,000 clinical nursing staff. Equipped with various series of da Vinci surgical robots and the Ion Bronchoscope Operation Control System (not yet launched in China), the da Vinci Innovation & Training Center features a surgical operating room capable of simultaneous training and operations for six da Vinci surgeries, an Ion simulation operating room, a training classroom for 40 people, and cutting-edge simulation training equipment, linked surgical beds, energy platforms, anesthesia machines, and other medical devices. Additionally, it includes multimedia conference rooms, a restaurant, a refreshment area, a maternity room, and changing rooms. Medical professionals can learn cutting-edge minimally invasive instruments and diagnostic techniques in such a simulated clinical environment. ...
- Source: drugdu
- 103
- December 27, 2023
Shanghai RAAS Cancels Limited Payment Scope of Medical Insurance for Some Products

According to the official website of the State Medical Insurance Bureau, in order to further improve the level of medication protection for the insured, in accordance with the Interim Measures for the Administration of Medicines for Basic Medical Insurance and the Requirements of the Work Program for Adjustment of the National Drug Catalogs for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance for the Year of 2023, the State Medical Insurance Bureau and the Ministry of Human Resources and Social Security have organized to adjust and formulate the “Drug Catalog (2023)” for the National Drug Catalog (2023)”, which was officially implemented from January 1, 2024 onwards. This catalog includes human albumin, IVIG (intravenous human immunoglobulin), human fibrinogen, human plasminogen complex, human coagulation factor VIII, human coagulation factor IX, human immunoglobulin, tetanus human immunoglobulin, human rabies immunoglobulin, and recombinant human coagulation factor VIIa, recombinant human coagulation factor VIII, and recombinant ...
- Source: drugdu
- 82
- December 25, 2023
MEDICA 2024

Name：MEDICA 2024 Time: Nov 11-14, 2024 Venue: Dusseldorf Exhibition Center City: Dusseldorf/ Germany Product categories: Medical equipment: medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, etc. Disposable consumables: disposable medical supplies, dressings and sanitary materials, various surgical instruments, etc. Medical equipment: Medical care equipment, home health care products, physical therapy, plastic surgery technology, etc. Medical periphery: Information and communication technology, medical services and publishing. About MEDICA: The MEDICA exhibition showcases the latest medical equipment, medical supplies, medical technology and services, covering various fields such as hospital equipment, surgical equipment, medical instruments, diagnostic equipment, rehabilitation equipment, and home medical supplies. Exhibitors can showcase their latest medical equipment and services at the fair, showing the strength and technical level of their companies to ...
- Source: drugdu
- 884
- December 20, 2023
“Magnetic Wave Knife” technology is here! Fosun Pharma and Insightec to establish a joint venture in China

On December 13, 2023, Fosun Pharma announced that its medical device subsidiary has signed a cooperation agreement with Insightec on December 12, to establish a joint venture in China, Fosun Insightec Medical Technology Company Limited* (hereinafter referred to as “Fosun Insightec”). Fosun Insightec will focus on the commercialization, clinical application and research of the Magnetic Resonance Guided Focused Ultrasound (MRFU) Brain Therapy System (i.e. Magnetic Wave Knife Brain Therapy System) in China, which will help Parkinson’s Disease patients and patients with idiopathic tremor to regain a high quality of life. In addition, Fosun Meditech plans to establish strategic partnerships with a number of medical centers in China to further explore the potential application of the Magnetic Wave Knife in neurological diseases and benefit a wider range of patients. Mr. Liu Yi, Senior Vice President of Fosun Pharma and Chairman and CEO of the Medical Device Division, said that he is ...
- Source: drugdu
- 172
- December 17, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.